Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Trends in Cancer Models 2021

Hervé Tiriac's Biography



Hervé Tiriac, Assistant Research Scientist, University of California-San Diego

Dr. Tiriac received his Ph.D. from UC San Diego studying pre-mRNA splicing and transcription with Dr. Tracy Johnson. Herve’s research focuses on developing systems for precision medicine that may be utilized in the fight against pancreatic cancer. Herve did his postdoctoral fellowship with David Tuveson at Cold Spring Harbor Laboratory where he collaborated with Hans Clevers to establish protocols for PDAC organoid generation and testing.

Hervé Tiriac Image

Pancreatic Cancer Patient-Derived Organoids as a Tool for Personalized Medicine

Thursday, 8 October 2020 at 09:45

Add to Calendar ▼2020-10-08 09:45:002020-10-08 10:45:00Europe/LondonPancreatic Cancer Patient-Derived Organoids as a Tool for Personalized MedicineTrends in Cancer Models 2021 in San Francisco, CaliforniaSan Francisco, CaliforniaSELECTBIOenquiries@selectbiosciences.com

Pancreatic cancer is the most lethal common solid malignancy. Systemic therapies are often ineffective and predictive biomarkers to guide treatment are urgently needed. We generated a pancreatic cancer patient-derived organoid (PDO) library that recapitulates the mutational spectrum and transcriptional subtypes of primary pancreatic cancer. New driver oncogenes were nominated and transcriptomic analyses revealed unique clusters. PDOs exhibited heterogeneous responses to standard-of-care chemotherapeutics and investigational agents. In a case study manner, we find that PDO therapeutic profiles paralleled patient outcomes and that PDOs enable longitudinal assessment of chemo-sensitivity and evaluation of synchronous metastases. We derived organoid-based gene expression signatures of chemo-sensitivity that predicted improved responses for many patients to chemotherapy in both the adjuvant and advanced disease settings. Finally, we nominated alternative treatment strategies for chemo-refractory PDOs using targeted agent therapeutic profiling. We propose that combined molecular and therapeutic profiling of PDOs may predict clinical response and enable prospective therapeutic selection.


Add to Calendar ▼2021-04-19 00:00:002021-04-19 00:00:00Europe/LondonTrends in Cancer Models 2021Trends in Cancer Models 2021 in San Francisco, CaliforniaSan Francisco, CaliforniaSELECTBIOenquiries@selectbiosciences.com